| The FDA-approved drug sofosbuvir inhibits Zika virus infection KM Bullard-Feibelman, J Govero, Z Zhu, V Salazar, M Veselinovic, ... Antiviral research 137, 134-140, 2017 | 261 | 2017 |
| Development and characterization of recombinant virus generated from a New World Zika virus infectious clone J Weger-Lucarelli, NK Duggal, K Bullard-Feibelman, M Veselinovic, ... Journal of virology 91 (1), 10.1128/jvi. 01765-16, 2017 | 132 | 2017 |
| A sensitive DNA capacitive biosensor using interdigitated electrodes L Wang, M Veselinovic, L Yang, BJ Geiss, DS Dandy, T Chen Biosensors and Bioelectronics 87, 646-653, 2017 | 114 | 2017 |
| Topical gel formulation of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 confers protection against HIV-1 vaginal challenge in a humanized mouse model M Veselinovic, CP Neff, LR Mulder, R Akkina Virology 432 (2), 505-510, 2012 | 106 | 2012 |
| HIV pre-exposure prophylaxis: mucosal tissue drug distribution of RT inhibitor Tenofovir and entry inhibitor Maraviroc in a humanized mouse model M Veselinovic, KH Yang, J LeCureux, C Sykes, L Remling-Mulder, ... Virology 464, 253-263, 2014 | 50 | 2014 |
| Zika viral infection and neutralizing human antibody response in a BLT humanized mouse model K Schmitt, P Charlins, M Veselinovic, L Kinner-Bibeau, S Hu, J Curlin, ... Virology 515, 235-242, 2018 | 25 | 2018 |
| Modeling HIV-1 mucosal transmission and prevention in humanized mice M Veselinovic, P Charlins, R Akkina HIV Protocols, 203-220, 2016 | 19 | 2016 |
| Monosodium glutamate induces apoptosis in naive and memory human B cells. Z Jovic, M Veselinovic, K Vasic, D Stankovic-Djordjevic, S Cekic, ... Bratislavske lekarske listy 110 (10), 636-640, 2009 | 11 | 2009 |
| Mucosal tissue pharmacokinetics of the integrase inhibitor raltegravir in a humanized mouse model: Implications for HIV pre-exposure prophylaxis M Veselinovic, KH Yang, C Sykes, L Remling-Mulder, ADM Kashuba, ... Virology 489, 173-178, 2016 | 10 | 2016 |
| Preclinical development of ASC-618, an advanced human factor VIII gene therapy vector for the treatment of hemophilia A: Results from FRG-KO humanized liver mice, C57Bl/6 mice … M Veselinovic, A Gilam, A Ross, C Yang, Y Zhang, T Jaitly, V Pak, A Bhatt, ... Mol Ther 28 (4), 167-8, 2020 | 3 | 2020 |
| Avian influenza A/H5N1 M Veselinovic Acta Medica Medianae 46 (3), 45-52, 2007 | 2 | 2007 |
| Site-Specific Genome Editing by CRISPR/Cas9 for Hemophilia A in Human and Non-Human Primate Cells A Gilam, Y Zhang, M Veselinovic, A Bhatt, C Yang, T Jaitly, X Wang, ... MOLECULAR THERAPY 27 (4), 239-240, 2019 | 1 | 2019 |
| CHANGES ON HELA CELL CULTURE IN PRESENCE ON ACRYLIC RESINS. M Kostić, N Krunić, S Najman, J Kocić, M Veselinović Acta stomatologica Naissi 24 (58), 2008 | 1 | 2008 |
| ASC618, a Second Generation of FVIII Gene Therapy for Hemophilia A, Exhibits Major Transduction and Transgene Expression in the Target Liver Tissues: Results of IND-Enabling … C Yang, T Sawant, A Gilam, Y Zhang, E Dewangan, M Veselinovic, ... MOLECULAR THERAPY 30 (4), 591-591, 2022 | | 2022 |
| Pharmacology, Toxicology and Safety Studies of ASC618, a Second Generation Factor VIII Gene Therapy for Hemophilia A Z Gluzman-Poltorak, C Yang, A Gilam, T Sawant, Y Zhang, E Dewangan, ... MOLECULAR THERAPY 30 (4), 367-367, 2022 | | 2022 |
| Adeno-Associated Virus Serotypes Screening in Non-Human Primates for Hemophilia A Genome Editing Treatment Z Gluzman-Poltorak, A Gilam, Y Zhang, I Afrikanova, H Chen, M Shi, ... MOLECULAR THERAPY 27 (4), 99-99, 2019 | | 2019 |
| Pharmacokinetic and pharmacodynamic evaluation of HIV-1 pre-exposure prophylaxis candidates in humanized mice M Veselinovic Colorado State University. Libraries, 2014 | | 2014 |
| Utachee et al. Retrovirology 2014, 11: 32 RS Veazey, RJ Shattock, M Pope, JC Kirjan, J Jones, Q Hu, I Ketas, ... | | |
Zhe (Jason) Zhu MD, PhDColumbia University Irving Medical Center/NewYork-Presbyterian HospitalVerified email at cumc.columbia.edu
